Altimmune has taken another step to claim its share in the growing obesity drug market with new data showing its drug pemvidutide (ALT-801) can induce weight loss and reduce dyslipidemia.
The Maryland, US-based company presented data from the Phase II MOMENTUM trial (NCT05295875) at the weight…
[ad_2]
Source link
